Susceptibility Profile of Novel Drug: Levonadifloxacin Against Multi-Drug Resistant MRSA (MDRSA) Isolates in a Tertiary Care Hospital, Mysore

Background & Objectives: Antibiotics have become a significant concern due to the rising mortality rates from Staphylococcus aureus infections and the emergence of methicillin-resistant and other multidrug-resistant strains. Levonadifloxacin is a novel antibiotic belonging to the benzoquinolizine, subclass of quinolone formulated for intravenous and oral administration, approved for the treatment of acute bacterial skin and soft tissue infections, respiratory infections, and concurrent bacteremia. The objective of this study is to assess the susceptibility profile of Levonadifloxacin against multidrug resistant MRSA isolates in-vitro. Methods: A total of 100 MRSA isolates were collected from July 2023 to March 2024. Susceptibility of Levonadifloxacin and other antibiotics were determined using the disk diffusion method as per recommendations of the Clinical and Laboratory Standards Institute. Results: Against all MRSA isolates, the drug susceptibilities were Gentamicin (29%), Doxycycline (50%), Ciprofloxacin (8%), Levofloxacin (9%), Cotrimoxazole (54%), respectively while Levonadifloxacin showed 100% susceptibility. Linezolid showed 99% susceptibility. Conclusion: Levonadifloxacin is a newer and safer treatment option for multi-drug resistant MRSA isolates. Key words: Levonadifloxacin, Multi-drug resistant MRSA, Antibiotic susceptibility, QRSA, Skin and soft tissue infections.